Hervé Bouillonnec

About Hervé Bouillonnec

Hervé Bouillonnec, age 55, is Chief Commercial Officer at Interparfums, USA LLC (wholly owned subsidiary), overseeing commercial strategy and licensing acquisitions; he joined Interparfums USA in May 2007 after roles at Yves Saint Laurent (Kering) and Givenchy (LVMH). He is a nominee to join the Interparfums, Inc. board as part of a proposed expansion from 9 to 11 directors in 2025; education includes a BA in European Business (Great Britain) and a Master of European Economics (University of Barcelona), and he is fluent in French, Spanish, and English .

Past Roles

External Roles

Board Governance

• Status: Director nominee for 2025; board proposed to expand to 11 members including Bouillonnec and Patrick Bousquet‑Chavanne .
• Independence: Not listed among independent directors; as a current executive of a subsidiary (Interparfums, USA LLC), he would not meet Nasdaq “independent” status if elected .
• Committees: No committee assignments disclosed for nominees; 2024 standing committees and members were: Audit (Chair: François Heilbronn; members: Robert Bensoussan, Veronique Gabai‑Pinsky), Executive Compensation & Stock Option (Chair: François Heilbronn; members: Robert Bensoussan, Veronique Gabai‑Pinsky), Nominating (Chair: François Heilbronn; members: Robert Bensoussan, Veronique Gabai‑Pinsky) .
• Attendance: The board held 23 meetings (and committee meetings/consents) in 2024; all incumbent directors attended at least 75% of meetings. Bouillonnec was not on the board in 2024, so attendance is not applicable .
• Lead Independent Director: None; Chair/CEO roles combined; board cites comfort with co-founders leading U.S. and European segments .

Fixed Compensation

• As a nominee, no director compensation for Bouillonnec is disclosed for 2024. Interparfums’ nonemployee director program (for independent directors) provides:
  • $6,000 per in‑person board meeting; $3,000 per telephonic meeting .
  • Audit Committee annual fee: $8,000 .
  • Automatic annual stock option grant for nonemployee directors: 1,500 shares on the last business day of each year at fair market value, vesting 20% annually over five years (fully vested at start of year 6). On 12/31/2024, options to purchase 1,500 shares at $130.60 were granted to five independent directors .
• Note: Because Bouillonnec is an operating executive of a subsidiary, if elected he would not be a nonemployee independent director and therefore would not be eligible for the independent director option program as currently structured .

Performance Compensation

• No director performance compensation disclosed for Bouillonnec. For context, the nonemployee director option program parameters are: | Item | Value | |---|---| | Annual independent director grant | 1,500 options (grant on last business day of year) | | Exercise price | Fair market value on grant date (e.g., $130.60 on 12/31/2024) | | Vesting | 20% annually, years 1–5; fully vested at start of year 6 | | Attendance adjustment | Grants reduced if board meeting attendance thresholds not met |

Other Directorships & Interlocks

Expertise & Qualifications

• 18+ years at Interparfums USA with leadership of global fragrance commercialization, licensing, and brand growth; prior luxury brand management at YSL (Kering) and Givenchy (LVMH) .
• Education: BA European Business (Great Britain); Master of European Economics (University of Barcelona); multilingual (French/Spanish/English) .
• Deep sector experience across prestige beauty and fragrance; cross‑market leadership including travel retail .

Equity Ownership

Governance Assessment

• Independence and conflicts: Bouillonnec is a current executive (CCO) of a wholly owned subsidiary; if elected, he would be a non‑independent director. He would also be ineligible for the independent director compensation/option program. This reduces the proportion of independent oversight and may constrain committee placement (Audit, Compensation, Nominating require independence) .
• Ownership alignment: No beneficial ownership of IPAR common stock reported; no options reportable within 60 days. Lack of equity ownership can signal lower “skin‑in‑the‑game” versus independent directors who participate in equity grants, though company‑wide anti‑hedging policy is a positive control .
• Board effectiveness signals: The board met frequently in 2024 (23 meetings) with all directors meeting ≥75% attendance; committees are fully independent and chaired by an experienced financial operator. The board is adding two seats (including Bouillonnec), which suggests a refresh/expansion; however, the absence of a Lead Independent Director persists as a structural consideration .

RED FLAGS

• Not independent (current operating executive), limiting eligibility for key oversight committees and potentially weakening the ratio of independent directors on the board .
• No disclosed IPAR equity ownership (0%), which reduces direct alignment with public shareholders absent a disclosed ownership plan for this nominee .

Mitigants/Controls

• Anti‑hedging policy in place for officers and directors .
• Independent committees (Audit, Compensation, Nominating) maintained and chaired by an independent director; board‑level related party approvals routed through Audit Committee .